Literature DB >> 11163656

Encouraging prospects for immunisation against primary cytomegalovirus infection.

P D Griffiths1, A McLean, V C Emery.   

Abstract

Congenital cytomegalovirus (CMV) infection is the leading infectious cause of mental retardation in children. Using seroprevalence data from two large antenatal populations (in excess of 14000 women) coupled with a mathematical modelling approach, we have shown that CMV has a low force of infection (ca. 0.03 per seronegative per annum) and its basic reproductive number R0 is relatively modest at 2.4. On the basis of these results, the critical vaccination proportion required for eradication of CMV is between 59-62%. In contrast to the predicted and observed effects of rubella vaccination on the incidence of congenital rubella, the increase in the average age of infection following instigation of a CMV vaccine programme will not increase the number of congenital infections. In conclusion, CMV is a prime candidate for eradication from the human population through vaccination.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11163656     DOI: 10.1016/s0264-410x(00)00377-7

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  28 in total

1.  National serosurvey of cytomegalovirus in Australia.

Authors:  Holly Seale; C Raina MacIntyre; Heather F Gidding; J L Backhouse; Dominic E Dwyer; Lyn Gilbert
Journal:  Clin Vaccine Immunol       Date:  2006-09-06

2.  Incidence of cytomegalovirus infection in Shanghai, China.

Authors:  Feng-Qin Fang; Qi-Shi Fan; Zhi-Jun Yang; Yi-Bing Peng; Li Zhang; Ke-Zi Mao; Yue Zhang; Yu-Hua Ji
Journal:  Clin Vaccine Immunol       Date:  2009-09-23

Review 3.  Priorities for CMV vaccine development.

Authors:  Philip R Krause; Stephanie R Bialek; Suresh B Boppana; Paul D Griffiths; Catherine A Laughlin; Per Ljungman; Edward S Mocarski; Robert F Pass; Jennifer S Read; Mark R Schleiss; Stanley A Plotkin
Journal:  Vaccine       Date:  2013-10-13       Impact factor: 3.641

4.  Higher Expectations for a Vaccine To Prevent Congenital Cytomegalovirus Infection.

Authors:  Soren Gantt; Arnaud Marchant; Suresh B Boppana
Journal:  J Virol       Date:  2018-07-17       Impact factor: 5.103

5.  Choice of Study Populations for Vaccines.

Authors:  Paul Griffiths; Brenna Hughes
Journal:  J Infect Dis       Date:  2020-03-05       Impact factor: 5.226

6.  Immune Correlates of Protection Against Human Cytomegalovirus Acquisition, Replication, and Disease.

Authors:  Cody S Nelson; Ilona Baraniak; Daniele Lilleri; Matthew B Reeves; Paul D Griffiths; Sallie R Permar
Journal:  J Infect Dis       Date:  2020-03-05       Impact factor: 5.226

Review 7.  Immunobiology of congenital cytomegalovirus infection of the central nervous system—the murine cytomegalovirus model.

Authors:  Irena Slavuljica; Daria Kveštak; Peter Csaba Huszthy; Kate Kosmac; William J Britt; Stipan Jonjić
Journal:  Cell Mol Immunol       Date:  2014-07-21       Impact factor: 11.530

Review 8.  Progress toward Development of a Vaccine against Congenital Cytomegalovirus Infection.

Authors:  Mark R Schleiss; Sallie R Permar; Stanley A Plotkin
Journal:  Clin Vaccine Immunol       Date:  2017-12-05

Review 9.  Neuropathogenesis of congenital cytomegalovirus infection: disease mechanisms and prospects for intervention.

Authors:  Maxim C-J Cheeran; James R Lokensgard; Mark R Schleiss
Journal:  Clin Microbiol Rev       Date:  2009-01       Impact factor: 26.132

10.  Trends in hospitalizations for diagnosed congenital cytomegalovirus in infants and children in Australia.

Authors:  Holly Seale; Robert Booy; C Raina MacIntyre
Journal:  BMC Pediatr       Date:  2009-01-26       Impact factor: 2.125

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.